Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Bruker Corp

NASDAQ: BRKR · Industrial Applications and Services · 6 alerts · CIK 1109354

Share price
$60.62Close, Nov 16
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bruker Corp filings on SEC EDGAR ↗

4:03 PM ET 10-Q
Financial Results

Bruker Q3 2026 Results: Net Loss of $112M, Loss Widens

Bruker Corporation reported a consolidated net loss of $109.7 million for the third quarter of 2026, compared to a loss of $58.5 million in the prior year period, primarily driven by a $174.5 million goodwill impairment charge. Despite the net loss, total revenue grew slightly to $874.0 million from $860.5 million year-over-year, supported by growth in service and other revenue.

Key figure
Net loss $112M
7:01 AM ET 8-K
Financial Results

Bruker Financial Results

Bruker Corp reported Q3 2026 revenue of $874.0 million, a 1.6% increase year-over-year, and a non-GAAP operating margin expansion of 400 basis points to 16.3%. Despite a GAAP diluted loss per share of $(0.81) due to non-cash goodwill impairment charges, non-GAAP diluted EPS grew 24.4% to $0.56. The company reconfirmed its full-year 2026 organic revenue growth and non-GAAP EPS guidance.

Term
Q3 2026

“Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successful drug development and useful AI frontier models. Together with strong growth-drivers in infectious disease diagnostics, and in deep-tech and semiconductor metrology, we are poised for growth acceleration.”

Frank H. Laukien, Bruker’s President and CEO

“In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one. We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”

Frank H. Laukien, Bruker’s President and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.